EU Moves To Ease Regulatory Burden On Pharma
Authorities Allow Flexibility During COVID-19 Pandemic
Executive Summary
Regulatory authorities have adapted the EU medicines framework to help pharmaceutical companies cope with the consequences of the COVID-19 pandemic.
You may also be interested in...
Europe's COVID-19 Procedures ‘Must Not Be Delayed’
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.
EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events
Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.
Coronavirus Update: Searching For A Treatment
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.